The Journal of Current Hematology & Oncology Research regularly publishes internationally qualified research in hematology and oncology within the current scholarly knowledge. This journal is indexed by indices that are considered international scientific journal indices (DRJI, ESJI, OAJI, etc.). According to the current Associate Professorship criteria, it is within the scope of International Article 1-d. Each article published in this journal corresponds to 5 points.

EndNote Style
Original Article
Evaluation of the relationship between immunohistochemical markers and the prognosis of patients with hepatocellular carcinoma
Aims: This study aimed to evaluate whether prognosis and survival time in patients hepatocellular carcinoma (HCC) were associated with immunohistochemistry results for Heat Shock Protein 70 (HSP70), Glutamine synthetase (GS), Cyclase Associated Protein 2 (CAP2), Enhancer of zeste homolog 2 (EZH2) and B-cell-specific Moloney murine leukemia virus integration site 1 (Bmi-1).
Methods: In this retrospective study, the medical records of 50 HCC cases were evaluated. Tissues were stained for the targeted antigens. Immunohistochemical stains were scored for cytoplasmic (HSP70, GS, CAP2) or nuclear (EZH2, Bmi-1) staining patterns under light microscopy.
Results: Twenty-nine (58%) of the HCC cases died and the overall survival time was 30±3 (24-37) months. Survival times were similar in terms of age (p=0.262), sex (p=0.707), cause of disease (p=0.655), tumor size (p=0.191) and degree of differentiation (p=0.280). The overall survival of HCC patients with vascular invasion was shorter (p=0.019). The frequency of EZH2 (p=0.025) and Bmi-1 (p=0.004) +/++ was higher in patients with vascular invasion. No correlation was found between overall survival time and HSP70 positivity (p=0.140) and CAP2 positivity (p=0.278); however, survival time was significantly shorter in HCC cases stained (++/+++) with EZH2 (p=0.034), Bmi-1 (p=0.008) and GS (p=0.018).
Conclusion: The results of this study showed that GS, EZH2, and Bmi-1 predicted prognosis and survival time in patients with HCC, possible due to relationships with vascular invasion. There is a need for more comprehensive, population-based studies on biomarkers that can be used in prognosis monitoring of HCC cases.

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A.Global cancer statistics 2018: GLOBOCAN estimates of incidence andmortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin.2018;68(6):394-424.
2. Akinyemiju T, Abera S, Ahmed M, et al. The burden of primary livercancer and underlying etiologies from 1990 to 2015 at the global,regional, and national level: results from the global burden of diseasestudy 2015. JAMA Oncol. 2017;3(12):1683-1691.
3. Toh MR, Wong EYT, Wong SH, et al. Global epidemiology and geneticsof hepatocellular carcinoma. Gastroenterol. 2023;164(5):766-782.
4. Llovet JM, Castet F, Heikenwalder M, et al. Immunotherapies forhepatocellular carcinoma. Nat Rev Clin Oncol. 2022;19(3):151-172.
5. Sakamoto M, Mori T, Masugi Y, Effendi K, Rie I, Du W. Candidatemolecular markers for histological diagnosis of early hepatocellularcarcinoma. Intervirol. 2008;51(Suppl 1):42-45.
6. Pinero F, Dirchwolf M, Pessoa MG. Biomarkers in hepatocellularcarcinoma: diagnosis, prognosis and treatment response assessment.Cells. 2020;9(6):1370.
7. Wang H, Pan K, Zhang HK, et al. Increased polycomb-group oncogeneBmi-1 expression correlates with poor prognosis in hepatocellularcarcinoma. J Cancer Res Clin Oncol. 2008;134(5):535-541.
8. Sakamoto K, Ogawa K, Tohyama T, et al. Serosal invasion is a strongprognostic factor for hepatocellular carcinoma after hepatectomy.Hepatol Res. 2019;49(4):419-431.
9. Alawyia B, Constantinou C. Hepatocellular carcinoma: a narrativereview on current knowledge and future prospects. Curr Treat OptionsOncol. 2023;24(7):711-724.
10. Ding J, Wen Z. Survival improvement and prognosis for hepatocellularcarcinoma: analysis of the SEER database. BMC Cancer. 2021;21(1):1157.
11. Sarveazad A, Agah S, Babahajian A, Amini N, Bahardoust M.Predictors of 5 year survival rate in hepatocellular carcinoma patients.J Res Med Sci. 2019;24:86.
12. Luk JM, Lam CT, Siu AF, et al. Proteomic profiling of hepatocellularcarcinoma in Chinese cohort reveals heat-shock proteins (Hsp27,Hsp70, GRP78) up-regulation and their associated prognostic values.Proteomics. 2006;6(3):1049-1057.
13. Gehrmann M, Cervello M, Montalto G, et al. Heat shock protein 70serum levels differ significantly in patients with chronic hepatitis, livercirrhosis, and hepatocellular carcinoma. Front Immunol. 2014;5:307.
14. Diehl JA, Yang W, Rimerman RA, Xiao H, Emili A. Hsc70 regulatesaccumulation of cyclin D1 and cyclin D1-dependent protein kinase.Mol Cell Biol. 2003;23(5):1764-1774.
15. Calderwood SK, Khaleque MA, Sawyer DB, Ciocca D. Heat shockproteins in cancer: chaperones of tumorigenesis. Trends Biochem Sci.2006;31(3):164-172.
16. Joo M, Chi JG, Lee H. Expressions of HSP70 and HSP27 inhepatocellular carcinoma. J Korean Med Sci. 2005;20(5):829-834.
17. Lim SO, Park SG, Yoo JH, et al. Expression of heat shock proteins(HSP27, HSP60, HSP70, HSP90, GRP78, GRP94) in hepatitis B virus-related hepatocellular carcinomas and dysplastic nodules. World JGastroenterol. 2005;11(14):2072-2079.
18. Kang GH, Lee BS, Lee ES, Kim SH, Lee HY, Kang DY. Prognosticsignificance of p53, mTOR, c-Met, IGF-1R, and HSP70 overexpressionafter the resection of hepatocellular carcinoma. Gut Liver. 2014;8(1):79-87.
19. Dai W, Zong WX. Glutamine synthetase: a tumor suppressor inhepatocellular carcinoma? J Mol Cell Biol. 2023;15(1):mjad007.
20. Dai W, Shen J, Yan J, et al. Glutamine synthetase limits beta-catenin-mutated liver cancer growth by maintaining nitrogen homeostasis andsuppressing mTORC1. J Clin Invest. 2022;132(24):e161408.
21. Uthamalingam P, Das A, Behra A, Kalra N, Chawla Y. Diagnosticvalue of glypican3, heat shock protein 70 and glutamine synthetase inhepatocellular carcinoma arising in cirrhotic and non-cirrhotic livers. JClin Exp Hepatol. 2018;8(2):173-180.
22. Morita M, Nishida N, Sakai K, et al. Immunological microenvironmentpredicts the survival of the patients with hepatocellular carcinomatreated with anti-PD-1 antibody. Liver Cancer. 2021;10(4):380-393.
23. Fu J, Li M, Wu DC, Liu LL, Chen SL, Yun JP. Increased expression ofCAP2 indicates poor prognosis in hepatocellular carcinoma. TranslatOncol. 2015;8(5):400-406.
24. Mohammed MA, Moustafa Omar N, Mohammed SA, Galal Deiab A.Identification of cyclase-associated protein-2 as a novel biomarker forearly-stage hepatocellular carcinoma. J Clin Gastroenterol Hepatol.2017;1(3):26.
25. Steele JC, Torr EE, Noakes KL, et al. The polycomb group proteins,BMI-1 and EZH2, are tumour-associated antigens. Br J Cancer.2006;95(9):1202-1211.
26. Liu Y, Yang Q. The roles of EZH2 in cancer and its inhibitors. MedOncol. 2023;40(6):167.
27. Li X, Yang Z, Song W, et al. Overexpression of Bmi-1 contributes to theinvasion and metastasis of hepatocellular carcinoma by increasing theexpression of matrix metalloproteinase (MMP)-2, MMP-9 and vascularendothelial growth factor via the PTEN/PI3K/Akt pathway. Int J Oncol.2013;43(3):793-802.
28. Lee RM, Russell MC. Is screening for hepatocellular carcinomaeffective? Adv Surg. 2023;57(1):73-86.
29. Zhang L, Li HT, Shereda R, et al. DNMT and EZH2 inhibitors synergizeto activate therapeutic targets in hepatocellular carcinoma. Cancer Lett.2022;548:215899.
30. Fu WM, Zhu X, Wang WM, et al. Hotair mediates hepatocarcinogenesisthrough suppressing miRNA-218 expression and activating P14 andP16 signaling. J Hepatol. 2015;63(4):886-895.
Volume 2, Issue 2, 2024
Page : 33-40